Avalanche Biotechnologies Inc. (AAVL) 39.41 $AAVL
Avalanche Biotechnologies (AAVL) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 7:52AM CDT
Avalanche Biotechnologies' shares fell over 6% on the day following the volatility since Mar 12
AAVL: 39.41 (+0.81), ACOR: 33.91 (-0.29)
Avalanche Bio teams up with University of Washington on treatment for color blindness
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:19AM CDT
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness
GlobeNewswire - Wed Mar 25, 6:00AM CDT
Vision Experts Jay and Maureen Neitz Join Company's Scientific Advisory Board
AAVL: 39.41 (+0.81)
Jim Cramer's 'Mad Money' Recap: 5 'What If' Scenarios That Could Change Markets
at The Street - Mon Mar 23, 7:25PM CDT
Every good investor needs to challenge his or her thinking, Cramer says.
CY: 14.11 (-0.25), MMM: 166.05 (+2.55), MU: 26.68 (+0.01), NWBO: 7.46 (-0.21), SWKS: 100.13 (+1.30), FB: 83.19 (-0.11), STX: 53.08 (+0.32), XON: 46.30 (+3.30), WSM: 79.11 (+1.21), NXPI: 102.43 (+2.51), WDC: 92.93 (+0.20), INTC: 31.46 (-0.54), QRVO: 81.40 (+2.12), AAVL: 39.41 (+0.81), TWTR: 49.89 (-0.12), AAPL: 126.37 (+3.12), AVGO: 130.55 (+2.34), SNDK: 64.98 (+0.39)
Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015
GlobeNewswire - Wed Mar 18, 8:01AM CDT
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that it will host an Analyst and Investor Day on March 25, 2015 in New York. Avalanche management will be joined by other notable ophthalmology leaders to discuss its clinical programs in development as well as advancements in next-generation technology and vision for the future.
AAVL: 39.41 (+0.81)
Avalanche Biotech reports 4Q loss
Automated Insights - Thu Mar 05, 9:10AM CST
MENLO PARK, Calif. (AP) _ Avalanche Biotechnologies Inc. (AAVL) on Thursday reported a loss of $10.4 million in its fourth quarter.
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies misses by $0.17, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 8:17AM CST
AAVL: 39.41 (+0.81)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 35.00 (+0.47), OPHT: 48.00 (-1.09), GSK: 47.20 (+0.18), PFNX: 16.62 (+0.10), LPTN: 2.47 (-0.01), AGN: 240.22 (+2.88), AAVL: 39.41 (+0.81), OHRP: 2.81 (+0.07), NVS: 101.31 (+0.91)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TAX: 28.47 (-0.49), DAKT: 10.54 (+0.05), MSON: 12.66 (+0.22), AAVL: 39.41 (+0.81), SPPI: 6.11 (+0.10), TRAK: 38.78 (+0.16), FDML: 13.05 (+0.16), ROSE: 16.69 (+0.06)
Avalanche Biotechnologies (AAVL) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 7:51AM CST
Avalanche Biotechnologies, Inc. (AAVL) was a big mover last session, as the company saw its shares rise almost 9% on the day.
AAVL: 39.41 (+0.81), AFFX: 12.86 (+0.15)
Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
PR Newswire - Tue Feb 10, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
BIIB: 431.62 (+1.75), BCRX: 8.57 (+0.27), BOTA: 2.26 (-0.01), TECH: 100.64 (+1.60), AAVL: 39.41 (+0.81)
DigiSight Technologies, Inc. Announces Series B Financing
Business Wire - Mon Feb 09, 3:27PM CST
DigiSight Technologies, Inc. (DigiSight), a software company that integrates data from mobile tests into clinical settings, today announced it raised $7.8 million in a Series B financing. New investors Biosys Capital, Waycross Ventures, GE Ventures, and Lagunita LLC joined existing investors in the financing.
AAVL: 39.41 (+0.81)
Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:50PM CST
Avalanche Biotechnologies (AAVL) is expected to report fourth-quarter 2014 results on Feb 11.
ACT: 304.76 (+1.20), AAVL: 39.41 (+0.81), ACOR: 33.91 (-0.29), REGN: 459.78 (+5.28)
Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots
GuruFundPicks - at Seeking Alpha - Thu Jan 29, 7:04PM CST
BLUE: 123.89 (+9.48), ABMD: 73.47 (+3.16), AUXL: 36.47 (-0.06), ASPX: 100.36 (+29.45), AAVL: 39.41 (+0.81)
How Avalanche Biotech Could Snowball Through Nosebleed Valuations
Lotus Medical Group - at Seeking Alpha - Fri Jan 16, 10:09AM CST
AAVL: 39.41 (+0.81)
InsiderInsights.com Daily Round Up 1/15/15: ETE, OVAS, TWMC, GPC
InsiderInsights - at Seeking Alpha - Thu Jan 15, 11:44PM CST
TWMC: 3.75 (+0.13), OVAS: 38.18 (-5.29), GPC: 93.86 (+0.93), GNCMA: 15.71 (+0.23), UPLD: 6.86 (-0.30), ETE: 63.83 (+1.63), FUND: 7.32 (+0.06), SRE: 109.67 (+1.17), GOOG: 552.03 (+3.69), MFRM: 69.11 (+1.73), TNET: 35.03 (-0.22), BH: 418.93 (-2.85), WIW: 11.37 (+0.01), JPM: 60.96 (+1.41), LNKD: 255.19 (-1.52), CDNA: 5.53 (-0.08), SGNT: 23.23 (+0.40), AAVL: 39.41 (+0.81), ALCO: 52.72 (+1.68)
Avalanche prices secondary offering
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 12:47PM CST
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock
GlobeNewswire - Thu Jan 08, 8:00AM CST
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its public offering of 2,399,457 shares of its common stock at a public offering price of $59.00 per share, before underwriting discounts, commissions and estimated expenses. 2,009,457 of the shares of common stock are being offered by Avalanche and 390,000 of the shares are being offered by existing stockholders. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 359,918 shares of common stock from Avalanche. Avalanche will not receive any proceeds from the sale of the shares by the selling stockholders. As part of the underwriting process, all selling stockholders, as well as all officers and directors, have agreed to lock-up agreements for a period of 90 days following the follow-on offering. The follow-on offering is expected to close on January 13, 2015, subject to customary closing conditions.
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies (AAVL) Crumbles: Stock Falls by 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 7:52AM CDT
Avalanche Biotechnologies' shares fell over 6% on the day following the volatility since Mar 12
AAVL: 39.41 (+0.81), ACOR: 33.91 (-0.29)
Avalanche Bio teams up with University of Washington on treatment for color blindness
Seeking Alpha - at Seeking Alpha - Wed Mar 25, 8:19AM CDT
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies and the University of Washington Enter Into Exclusive License Agreement to Develop Gene Therapy Medicines to Treat Color Blindness
GlobeNewswire - Wed Mar 25, 6:00AM CDT
Vision Experts Jay and Maureen Neitz Join Company's Scientific Advisory Board
AAVL: 39.41 (+0.81)
Jim Cramer's 'Mad Money' Recap: 5 'What If' Scenarios That Could Change Markets
at The Street - Mon Mar 23, 7:25PM CDT
Every good investor needs to challenge his or her thinking, Cramer says.
CY: 14.11 (-0.25), MMM: 166.05 (+2.55), MU: 26.68 (+0.01), NWBO: 7.46 (-0.21), SWKS: 100.13 (+1.30), FB: 83.19 (-0.11), STX: 53.08 (+0.32), XON: 46.30 (+3.30), WSM: 79.11 (+1.21), NXPI: 102.43 (+2.51), WDC: 92.93 (+0.20), INTC: 31.46 (-0.54), QRVO: 81.40 (+2.12), AAVL: 39.41 (+0.81), TWTR: 49.89 (-0.12), AAPL: 126.37 (+3.12), AVGO: 130.55 (+2.34), SNDK: 64.98 (+0.39)
Avalanche Biotechnologies to Host Analyst and Investor Day on March 25, 2015
GlobeNewswire - Wed Mar 18, 8:01AM CDT
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that it will host an Analyst and Investor Day on March 25, 2015 in New York. Avalanche management will be joined by other notable ophthalmology leaders to discuss its clinical programs in development as well as advancements in next-generation technology and vision for the future.
AAVL: 39.41 (+0.81)
Avalanche Biotech reports 4Q loss
Automated Insights - Thu Mar 05, 9:10AM CST
MENLO PARK, Calif. (AP) _ Avalanche Biotechnologies Inc. (AAVL) on Thursday reported a loss of $10.4 million in its fourth quarter.
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies misses by $0.17, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Mar 05, 8:17AM CST
AAVL: 39.41 (+0.81)
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Pipeline Review 2015: 41 Companies
M2 - Tue Mar 03, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/pk77s7/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - AlphaMab Co., Ltd - Amakem NV - Avalanche Biotechnologies, Inc. - Bayer AG - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Circadian Technologies Limited - Clearside BioMedical, Inc. - EyeCyte, Inc. - F. Hoffmann-La Roche Ltd. - Genzyme Corporation - GlaxoSmithKline plc - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Iconic Therapeutics, Inc. - Intas Pharmaceuticals Ltd. - Kala Pharmaceuticals, Inc. - Lpath, Inc. - Mesoblast Limited - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pk...eovascular
PFE: 35.00 (+0.47), OPHT: 48.00 (-1.09), GSK: 47.20 (+0.18), PFNX: 16.62 (+0.10), LPTN: 2.47 (-0.01), AGN: 240.22 (+2.88), AAVL: 39.41 (+0.81), OHRP: 2.81 (+0.07), NVS: 101.31 (+0.91)
Nasdaq stocks posting largest percentage decreases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
TAX: 28.47 (-0.49), DAKT: 10.54 (+0.05), MSON: 12.66 (+0.22), AAVL: 39.41 (+0.81), SPPI: 6.11 (+0.10), TRAK: 38.78 (+0.16), FDML: 13.05 (+0.16), ROSE: 16.69 (+0.06)
Avalanche Biotechnologies (AAVL) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 7:51AM CST
Avalanche Biotechnologies, Inc. (AAVL) was a big mover last session, as the company saw its shares rise almost 9% on the day.
AAVL: 39.41 (+0.81), AFFX: 12.86 (+0.15)
Valuable Updates on Pharmaceutical Companies: New Research on Avalanche Biotechnologies, BioCryst, Biogen, Biota Pharmaceuticals, and Bio-Techne
PR Newswire - Tue Feb 10, 7:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
BIIB: 431.62 (+1.75), BCRX: 8.57 (+0.27), BOTA: 2.26 (-0.01), TECH: 100.64 (+1.60), AAVL: 39.41 (+0.81)
DigiSight Technologies, Inc. Announces Series B Financing
Business Wire - Mon Feb 09, 3:27PM CST
DigiSight Technologies, Inc. (DigiSight), a software company that integrates data from mobile tests into clinical settings, today announced it raised $7.8 million in a Series B financing. New investors Biosys Capital, Waycross Ventures, GE Ventures, and Lagunita LLC joined existing investors in the financing.
AAVL: 39.41 (+0.81)
Will Avalanche (AAVL) Miss This Earnings on Higher Costs? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 1:50PM CST
Avalanche Biotechnologies (AAVL) is expected to report fourth-quarter 2014 results on Feb 11.
ACT: 304.76 (+1.20), AAVL: 39.41 (+0.81), ACOR: 33.91 (-0.29), REGN: 459.78 (+5.28)
Winners Circle 2014 Top Hedge Fund Managers: Healthcare Funds, Nine Of Top Ten Spots
GuruFundPicks - at Seeking Alpha - Thu Jan 29, 7:04PM CST
BLUE: 123.89 (+9.48), ABMD: 73.47 (+3.16), AUXL: 36.47 (-0.06), ASPX: 100.36 (+29.45), AAVL: 39.41 (+0.81)
How Avalanche Biotech Could Snowball Through Nosebleed Valuations
Lotus Medical Group - at Seeking Alpha - Fri Jan 16, 10:09AM CST
AAVL: 39.41 (+0.81)
InsiderInsights.com Daily Round Up 1/15/15: ETE, OVAS, TWMC, GPC
InsiderInsights - at Seeking Alpha - Thu Jan 15, 11:44PM CST
TWMC: 3.75 (+0.13), OVAS: 38.18 (-5.29), GPC: 93.86 (+0.93), GNCMA: 15.71 (+0.23), UPLD: 6.86 (-0.30), ETE: 63.83 (+1.63), FUND: 7.32 (+0.06), SRE: 109.67 (+1.17), GOOG: 552.03 (+3.69), MFRM: 69.11 (+1.73), TNET: 35.03 (-0.22), BH: 418.93 (-2.85), WIW: 11.37 (+0.01), JPM: 60.96 (+1.41), LNKD: 255.19 (-1.52), CDNA: 5.53 (-0.08), SGNT: 23.23 (+0.40), AAVL: 39.41 (+0.81), ALCO: 52.72 (+1.68)
Avalanche prices secondary offering
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 12:47PM CST
AAVL: 39.41 (+0.81)
Avalanche Biotechnologies Prices Public Offering of $141.6 Million of Common Stock
GlobeNewswire - Thu Jan 08, 8:00AM CST
Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced the pricing of its public offering of 2,399,457 shares of its common stock at a public offering price of $59.00 per share, before underwriting discounts, commissions and estimated expenses. 2,009,457 of the shares of common stock are being offered by Avalanche and 390,000 of the shares are being offered by existing stockholders. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 359,918 shares of common stock from Avalanche. Avalanche will not receive any proceeds from the sale of the shares by the selling stockholders. As part of the underwriting process, all selling stockholders, as well as all officers and directors, have agreed to lock-up agreements for a period of 90 days following the follow-on offering. The follow-on offering is expected to close on January 13, 2015, subject to customary closing conditions.
AAVL: 39.41 (+0.81)
